Janna E. Hutz PhD, BS

Janna Hutz is the President of the Eisai Center for Genetics Guided Dementia Discovery. Dr. Hutz is a tremendous scientist and leader, who has made a sizeable impact on Eisai since joining the company. She has been instrumental in leading the progress we continue to make pursuing targets underpinned by human genetics that drive the underlying pathophysiology of dementia, said Ivan Cheung, President of the Neurology Business Group and Chairman of Eisai Inc. She takes the helm at G2D2 at a historic time in the battle against dementia and Alzheimer's disease. We are confident that under her leadership, our talented team will continue to develop and deliver innovative therapeutic solutions to address the unmet needs of patients.

Since joining Eisai in 2015, Dr. Hutz has played an integral role in Eisai's efforts to identify and validate genetically-supported targets for dementia, utilizing human biology and data science-driven target identification through early experimental validation. She most recently served as the Head of Discovery Data Science at G2D2, where she established and led a task force that provides comprehensive data analysis tailored to all of Eisai's 21 global Neurology Discovery programs. Dr. Hutz also served as the co-chair of an initiative that seeks to leverage human data to inform the company's pathophysiology-guided drug discovery approach. In her previous roles, she headed G2D2's IT, Informatics, and Translational Human Biology functions, and served four years as Head of Data Science & Scientific Infrastructure at the former Eisai Andover innovative Medicines (AiM) Institute, which was located in Andover, Mass.